Federal Funding Disruptions Slow Pace of Vision Science
More than a year after the National Institutes of Health (NIH) halted tens of thousands of research grant applications, scientists at Columbia University Irving Medical Center’s Department of Ophthalmology continue to operate under uncertainty.
Some of the department’s suspended grants have been restored, but many investigators are still waiting for their restored funding to come through. Other grants remain suspended, with investigators receiving few status updates.
The uncertainty has created a cascade of problems.
“It discourages long-term planning and risk-taking, especially for younger scientists,” says Xin Zhang, PhD, director of Vision Science Research and Malcolm P. Aldrich Research Professor of Ophthalmic Science.
“We depend on being able to plan years in advance, and when that becomes impossible, it’s very difficult to sustain momentum,” says Janet R. Sparrow, PhD, Anthony Donn Professor of Ophthalmic Science (in Ophthalmology) and professor of pathology and cell biology.
The unpredictability is felt most acutely by the department’s early- and mid-career investigators, who are in the critical phase of establishing laboratories and securing their first independent grants.
“When federal funding stalls, it isn’t only about dollars—it’s about timing,” says Kaveri A. Thakoor, PhD, MPhil, MS, assistant professor of ophthalmic science and director of the Artificial Intelligence for Vision Science Laboratory. Her team is building AI tools to detect and predict retinal disease progression, an area advancing at a rapid pace.
“AI and data-science projects move quickly, and every month lost can mean falling behind in a field that’s advancing daily.”
Like her colleagues, Dr. Thakoor has sought to bridge the gap through other avenues, including foundation grants and career-development awards.
For senior investigators such as Simon John, PhD, Robert L. Burch III Professor of Ophthalmic Science, whose pioneering work on glaucoma genetics has shaped the field for decades, the stakes may be even higher.
“When resources are uncertain, it’s not just experiments that are at risk. It’s the infrastructure that supports them,” he says. “You lose experienced staff, students reconsider research careers, and years of investment in animal models or specialized technology can be lost.”
Ironically, these pressures come at a time of extraordinary scientific promise.
“We’re entering a transformative era in vision science—an era of AI, gene therapy, and regenerative medicine,” says Dr. Zhang.
But these advances depend on sustained infrastructure, including people, technology, and stable funding. Philanthropic support has been essential for bridging gaps and keeping critical projects moving forward.
The current situation is not a passing disruption, but a serious threat to progress in vision science, says G.A. (Jack) Cioffi, MD, Jean and Richard Deems Professor, Edward S. Harkness Professor, and Chairman of the Department of Ophthalmology.
“The question is no longer whether discovery is possible,” says Dr. Cioffi, “but whether we will act quickly enough to prevent its promise from slipping out of reach for the patients who depend on it. This moment demands urgent action and renewed commitment to sustaining biomedical research.”